Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4300
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis.

    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
AB Science
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
AndroBioSys
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Aprea
Arana Therapeutics
Ardana
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
Bionovo
BioNumerik
BioSante
Biostar
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Cleveland BioLabs
Colby
CompleGen
Cornerstone Pharmaceuticals
Cosmo Bioscience
CritiTech
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Dongkook Pharm
Dyax
ECI
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Ferring
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
GammaCan
Gemin X Pharmaceuticals
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
Karo Bio
Karus Therapeutics
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
MolMed
Morvus Technology
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
SBIO
Scancell
SciClone Pharmaceuticals
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shionogi
Shire
Siena Biotech
Simcere Pharmaceuticals
Soligenix
Sophiris Bio
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
Supratek Pharma
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UCB
UMN Pharma
Unigene
United Biomedical
Vaxon Biotech
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroMed
ViroTarg
VM Discovery
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEG-35156
AEZS-108
afatinib
aflibercept
AGS-1C4D4
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
Angiozyme
apatinib
APC-100
APR-246
apricoxib
ARC-100
ARQ-197
atrasentan
AVX-701
axitinib
bafetinib
bardoxolone methyl
bevacizumab
BIBF-1120
bicalutamide
BMS-690514
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
buserelin
Cabozantinib
capecitabine
carlumab
catumaxomab
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CRLX-101
custirsen
dalotuzumab
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
endostatin
eniluracil
ENMD-2076
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
Exherin
figitumumab
flutamide
foretinib
fosbretabulin tromethamine
fulvestrant
ganitumab
gataparsen
GDC-0980
gefitinib
GliaAtak
goserelin
GSK-1120212
GT-111
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
IMP-321
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
JI-101
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
masitinib
MCS-110
MDV-3100
MetXia
MGCD-265
midostaurin
MKC-1
MLN-8237
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
Nab-docetaxel
nadroparin
NGR-TNF
nilutamide
nimotuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
orteronel
OTS-102
ozarelix
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
PF-4856884
plitidepsin
PLX-3397
ponatinib
ProstAtak
PROSTVAC
PRX-302
PTC-299
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
Rexin-G
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
RX-0201
sagopilone
sargramostim
SB-939
selumetinib
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
TAK-448
talactoferrin alfa
talminogene laherparepvec
tandutinib
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
TOK-001
toremifene citrate
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vismodegib
volociximab
WX-671
XL-184
XL-647
YM-155
Z-360
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis.
    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Lymphoma, Melanoma and Pancreatic Cancer. Learn More


Triple Analysis: Lung Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More


Prostate Cancer Drug Pathway Analyzer
There are today at least 503 targeted molecular therapies known to affect more than 255 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 305 of these have been recorded with mutations and 58 drug targets have mutations which have been causally implicated in cancer. Learn More